WASHINGTON (Reuters) - The U.S. Supreme Court on Monday declined to hear a Johnson & Johnson subsidiary's appeal of a $124 million penalty imposed by South Carolina after a jury found the drugmaker had improperly marketed the anti-psychotic drug Risperdal and concealed its risks.